(SeaPRwire) – By: Lucas Caldwell
Here’s the strange part of this story. Four blood tests for Alzheimer’s now carry FDA clearance. One of them works for patients as young as 40. Yet every expert quoted in this announcement agrees on one thing: if you feel fine, you shouldn’t touch these tests. A diagnostic breakthrough arrived, and the first instruction is restraint. That tension deserves attention. Medicine rarely tells people to wait after a tool gets approved. It happened here because the tool measures biology, not illness, and biology shows up years before symptoms do.
The timeline matters. Fujirebio got the first clearance in May 2025, with a test measuring the ratio of two Alzheimer’s proteins, a form of beta amyloid and a form of tau. It requires specialized equipment, so commercial labs mostly can’t run it. Roche followed in October 2025 with a tau-based test that primary care doctors can prescribe to rule out the disease. Then August brought two more. C2N’s PrecivityAD2 uses mass spectrometry to generate a probability score for amyloid plaques. Roche’s Elecsys ptau217 plasma test hunts a modified tau that appears when amyloid starts building up.
The fine print defines who qualifies. These tests target people already showing memory lapses or cognitive complaints. They are not screening tools for healthy adults. Dr. Lawren VandeVrede at UCSF put it bluntly: he worries about inappropriate use in patients without symptoms. Traditional workups, checking medications, mood, and other contributors, already hit about 85% diagnostic accuracy. Blood tests push that higher. Dr. Thomas Wisniewski at NYU Langone calls the ptau217 test the most useful, with the highest sensitivity and specificity. But he stresses these tests measure risk, not certainty.
Now the uncomfortable math. Dr. Jason Hinman at UCLA points to published research suggesting a third of cognitively intact older people would test positive for Alzheimer’s biomarkers, including on blood tests. Read that again. One third. Positive results, no symptoms. Testing the worried well would flood clinics with anxious patients holding ambiguous numbers and no proven treatment path. False positives climb in lower-risk populations. That’s not a minor caveat. It’s the entire reason the FDA clearances come wrapped in restrictions, and why doctors are drawing bright lines around who gets tested.
The real prize sits in two ongoing trials. Both enroll people without memory problems who carry abnormal brain proteins, testing whether lecanemab or donanemab can clear that buildup and slow progression. Results could arrive within a year or so. If either drug works in pre-symptomatic patients, everything flips. Blood tests stop being diagnostic assistants and become population-scale screening infrastructure. Dr. Eric Reiman at Banner Alzheimer’s Institute frames the ambition plainly: personalizing Alzheimer’s care the way cancer care works, with diagnosis, prognosis, and staging all informed by biomarkers.
Watch the payer decisions after those trial readouts, because reimbursement, not FDA clearance, decides whether a vial of blood becomes medicine’s cheapest crystal ball.
Author bio: Lucas Caldwell, a tech and science opinion leader with millions of followers on X/Twitter, covering the collision of diagnostics, drug development, and healthcare economics.